Uveitis Biomarker Panels for Rapid Infectious Cause Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing intraocular infections, such as uveitis, are delayed by laboratory cultures, leading to debilitating visual morbidity and blindness due to the inability to quickly identify microbial agents causing infectious endophthalmitis.
Innovation Solution
The use of biomarkers like PGLYRP1, ELANE, MMP9, S100A8, SPARCL1, LRP2, CNMD, CHIT1, MPO, LCN2, LCP1, CST4, CNTN1, HPD, MINP1, MMP8, and SERPINA3 for distinguishing infectious uveitis from non-infectious uveitis and further differentiating between bacterial, viral, and fungal uveitis, combined with clinical parameters for diagnosis and treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If microbial culture methods are used to diagnose intraocular infections, then diagnostic accuracy is improved, but diagnosis time is significantly delayed
Solution Approach 1:
The patent extracts and measures specific biomarkers (peptidoglycan, beta-glucan, cholesterol) directly from vitreous humor samples using biochemical assays, eliminating the need to wait for microbial culture growth. This extraction approach allows rapid identification of infection type within hours rather than days or weeks.
Solution Approach 2:
The patent changes the diagnostic parameter from detecting microbial presence via culture to measuring host response biomarker levels through biochemical assays. By quantifying peptidoglycan, beta-glucan, and cholesterol levels, the system rapidly determines infection type without waiting for microbial identification.
2Speed
If clinical examination alone is used to diagnose uveitis, then diagnostic speed is improved, but diagnostic precision deteriorates
Solution Approach 1:
The patent replaces mechanical clinical examination with biochemical measurement systems that quantify specific biomarker levels. This substitution maintains rapid diagnosis while significantly improving precision by objectively measuring peptidoglycan, beta-glucan, and cholesterol levels rather than relying on subjective clinical assessment.
Solution Approach 2:
The patent introduces biomarker measurement as an intermediary between clinical examination and diagnosis. By measuring host response biomarkers (peptidoglycan for bacterial, beta-glucan for fungal, cholesterol patterns) in the vitreous humor, the system bridges the gap between rapid examination and precise diagnostic confirmation.
3Reliability
If waiting for culture results is required, then treatment accuracy is improved, but treatment timing is delayed
Solution Approach 1:
The patent performs preliminary identification of infection type by measuring biomarker levels immediately upon sample collection, before culture results are available. This preliminary action allows clinicians to initiate appropriate antimicrobial therapy (bacterial, fungal, or viral) without waiting for definitive culture confirmation, improving treatment timing while maintaining accuracy through subsequent culture verification.
Data Source
AI summary
Compositions, methods, and kits are provided for diagnosing and treating uveitis. In particular, biomarkers have been identified that can be used to distinguish infectious uveitis from noninfectious uveitis, and further discriminate among bacterial, viral, and fungal uveitis. These biomarkers can be used alone or in combination with one or more additional biomarkers or relevant clinical parameters in prognosis, diagnosis, or monitoring treatment of uveitis.